General description
Lentiviral particles (representational, plate titer) are provided in 96-well plates that are barcoded for simple identification. Aliquots of 4 x 50μl are provided to prevent the need for excessive freeze/thaw, and maximize functional viral particles. Each gene family set is representationally titered (10% of clones). Fully titered sets are also available, for more information inquire at RNAi@sial.com. A CD containing RefSeq, gene description, gene symbol, clone ID, hairpin sequence, locus link, and plate map positions are provided with the gene family set.
Other Notes
Each MISSION shRNA clone is constructed within the lentivirus plasmid vector, pLKO.1-Puro, followed by transformation into Escherichia coli. The pLKO.1-Puro vector contains bacterial (ampicillin) and mammalian (puromycin) antibiotic resistance genes for selection of inserts in either bacterial or mammalian cell lines. Each clone set consists of an average of 3-5 constructs that have been designed against each target gene using a proprietary algorithm. Therefore, a range of knockdown efficiency, with at least one construct from each gene set being >70%, can be expected when using these clones. This allows one to examine the effect of loss of gene function over a large series of gene knockdown efficiencies. Each shRNA construct has been cloned and sequence verified to ensure a match to the target gene.
For a detailed listing of other available gene family sets, visit the gene family set website.
Number of Genes:746, Number of Clones: 9418
Avg. Clones per Gene: 12.6
Avg. Clones per Gene: 12.6
The exact gene and clone count at time of purchase may vary slightly as the TRC library is continually updated.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense .
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
저장 등급
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
David Murdoch et al.
Current opinion in oncology, 20(1), 104-111 (2007-11-29)
(1) Many of the significant advances in cancer management in recent years have centered on the development and introduction of molecularly targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors.(2) Despite targeted therapy that has clearly benefited and even
G Manning et al.
Science (New York, N.Y.), 298(5600), 1912-1934 (2002-12-10)
We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences. This provides a starting point for comprehensive analysis of protein phosphorylation in normal and
Virendra S Gomase et al.
Current drug metabolism, 9(3), 255-258 (2008-03-14)
Kinomics is derived from the word kinome that is the kinase part of the proteome. Kinomics is a merger between genomics and proteomics. Defining the kinase complement of the human genome, the kinome, has provided an excellent starting point for
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| SH0131 | 04061823781008 |